Navigation Links
GSK to Acquire Reliant Pharmaceuticals
Date:11/21/2007

Addition of Lovaza to expand GSK cardiovascular portfolio in US Acquisition

provides sales, synergy benefits

LONDON, PHILADELPHIA and LIBERTY CORNER, N.J., Nov. 21 /PRNewswire- FirstCall/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Reliant Pharmaceuticals Inc. announced today that they had reached an agreement under which Reliant will be acquired by GSK for $1.65 billion (800 million pounds Sterling) in cash.

Reliant, a privately held specialty pharmaceutical company focused on cardiovascular therapies, recorded net sales of $341 million in the nine months ending September 30, 2007, an increase of 62% over the comparable time period a year earlier.

GSK expects the transaction will be slightly accretive to earnings in 2008, excluding integration costs, and will create additional value in following years.

Through its strategic in-licensing and development strategy, Reliant has developed a portfolio of specialty medicines combating heart disease, including US rights to Lovaza(TM) (omega-3-acid ethyl esters), a treatment for adult patients with very high levels of triglycerides. Triglycerides are fatty substances in the blood associated with increased risks of coronary artery disease. Lovaza is indicated as an adjunct to diet to reduce triglyceride levels in adults with very high (greater than or equal to 500 mg/dL) triglyceride levels.

High lipid levels continue to be a growing health problem in the United States, with up to 5 million people having triglyceride levels classified as very high. Lovaza is the only prescription omega-3 medicine approved by the US Food and Drug Administration for the treatment of very high triglycerides, and remains the only omega-3 medicine that, along with diet and exercise, has been clinically proven to provide a 45% reduction in triglycerides in adult patients with very high triglyceride levels.

Launched in late 2005, Lovaza (formerly known as Omacor(R)) achieved rapid uptake among patients and health care professionals. In the nine months ending September 30, 2007, net sales were $206 million, an increase of 115% over the first nine months of 2006.

Lovaza competes in the non-statin dyslipidemia segment of the US cardiovascular market, where it had achieved a 10% market share of total prescriptions as of September 30, 2007. Sales in the non-statin dyslipidemia market totaled approximately $2.2 billion in 2006 and are expected to grow in excess of 20% a year. GSK believes there is significant opportunity for future growth of Lovaza in this market segment.

Reliant licensed the rights to Lovaza in the US and Puerto Rico from Pronova BioPharma ASA (Oslo: PRON), a publicly traded Norwegian company that will continue to supply the product's primary material. Rights to Lovaza in other markets have been licensed by Pronova to several other companies.

Commenting on the acquisition agreement, Chris Viehbacher, President, US Pharmaceuticals, GSK, said, "The addition of Lovaza to the GSK portfolio adds a new driver of sales growth in the US business. It represents a strong strategic fit, complementing Coreg CR(R), a leading treatment for heart failure and hypertension, and adds to our growing profile in the cardiovascular disease area."

"Today is a momentous date for Reliant," said Bradley T. Sheares, CEO of Reliant. "We are very proud of the work that our employees have done to build this company, particularly the energy and perseverance of our sales teams, who have demonstrated their worth in building a formidable Lovaza franchise in less than 24 months. We see great additional potential through this acquisition for Lovaza and the patients who could benefit from it."

The acquisition is subject to approval by the US Federal Trade Commission and is expected to conclude before year-end.

In addition to Lovaza, Reliant Pharmaceuticals, based in Liberty Corner, NJ, currently markets three other in-licensed cardiovascular products - high blood pressure treatments DynaCirc CR(R) (isradipine) and InnoPran XL(R) (propanolol HCl), as well as Rythmol SR(R) (propafenone), which treats abnormal heart rhythms, or arrhythmia.

About GSK

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit http://www.gsk.com.

GlaxoSmithKline forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2006.

About Reliant Pharmaceuticals

Reliant Pharmaceuticals, Inc. is a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. Reliant currently markets four cardiovascular products in the United States and focuses on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and academic centers in the United States. Reliant's sales force infrastructure is comprised of approximately 880 sales and marketing professionals nationwide.

Reliant Pharmaceuticals forward-looking statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, and other factors that may cause Reliant's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Reliant's control and which could materially affect actual results, levels of activity, performance or achievements.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Food Bank For New York City Acquires FoodChange
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
6. UTC Power Acquires Dome-Tech Group
7. AMERIGROUP to Acquire Memphis Health Plan
8. Concentra Acquires Assets of Renew Health & Wellness
9. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
10. NNN Healthcare/Office REIT Acquires St. Mary Physicians Center in Long Beach, California
11. NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Brenton Engineering , powered by ... flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new ... semi-automatic or fully-automatic case packing with a small footprint, rugged, highly flexible, and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, a ... latest beneficiary of their ongoing community enrichment program. The current campaign fundraises for ... Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves ...
(Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
(Date:2/8/2016)... ... , ... Remember the old saying “rub some dirt on it”? Perhaps you ... “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet are ... A former motivational speaker, Perry A~ has since dedicated her life to learning about ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... SAN DIEGO , Feb. 9, 2016 ... developing novel, clinical-stage therapies for sickle cell disease and heart ... common stock and warrants to purchase common stock in an ... other conditions, and there can be no assurance as to ... to the actual size or terms of the offering.   ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 Hearing ... amount of sound energy transmitted to the inner ear. ... and hearing bands. These devices are recommended for users ... eight hours. Earplugs refer to HPD that are inserted ... attenuation earplugs are designed to provide more natural sound ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 This ... surgical interventions, reported by the ICD-9 coding system in ... to the surgical procedure volumes, the report provides written ... and dynamics of the local markets. In addition, the latest ... --> --> The ...
Breaking Medicine Technology: